News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Geron Corporation (GERN) Soars After Study Shows Bone Marrow Drug's Benefit


12/6/2013 7:40:27 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Geron Corp. (GERN) shares rose as much as 32 percent after a Mayo Clinic study found the biotechnology company’s experimental drug imetelstat helped patients with a bone marrow cancer. Geron increased 17 percent to $6.86 at 7:57 a.m. New York time after gaining to $7.73. The Menlo Park, California-based company’s shares had climbed more than three-fold this year through yesterday.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg

comments powered by Disqus
Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES